Flash-Player installieren
ScheBo-MediaBox



» Flash-Player installieren
ScheBo® Biotech AG
Netanyastrasse 3
35394 Giessen, Germany


Phone +49 -(0)641 -4996-0
Fax +49 -(0)641 -4996-77
Email-contact

ScheBo® Elastase 1 - Canine

Non-radioactive pancreatic function test for dogs


Weight Loss - Maldigestion in dogs !

Is the pancreas involved?

Weight loss and maldigestion (usually presenting as steatorrhoea) are two of the main clinical symptoms suggestive of pancreatic exocrine insufficiency in dogs. A diagnosis or exclusion of this condition is then required.

Exocrine pancreatic insufficiency is very often only diagnosed as a reason for weight loss, maldigestion and /or steatorrhoea at an advanced stage of disease. However, an early diagnosis of exocrine pancreatic insufficiency allows early initiation of successful treatment with pancreatic enzymes substitution therapy.

ScheBo® Elastase 1- Canine is a non-radioactive and highly sensitive and specific assay for the determination of canine pancreatic elastase 1 (E1) in faeces, which reflects the exocrine capacity of the pancreas.

ScheBo® Elastase 1- Canine is an ELISA test based on monoclonal antibodies and guarantees a reliable diagnosis of exocrine pancreatic insufficiency even under pancreatic enzyme substitution therapy. Using this test exocrine pancreatic insufficiency can be distinguished from intestinal diseases and hepatobiliary disorders affecting the small intestine.


Indications and main advantages

  • Diagnosis or exclusion of exocrine pancreatic insufficiency caused by, for example, pancreatic acinar atrophy, pancreatic cancer, chronic pancreatitis, parasites or stones.
  • E1 is absolutely pancreas-specific.
  • The test is non-radioactive. An isotopic laboratory is not required.
  • A single pea-sized stool sample is sufficient.
  • High stability of pancreatic elastase 1 allows time for convenient mailing.
  • No need to interrupt substitution therapy.
  • There is no need for a 12-hour starvation period, in contrast to the necessary preparation before the cTLI test.




A Decade of UK Success for Schebo Biotech
ScheBo® Biotech UK Limited, a leading provider of unique in-vitro diagnostic tests for the healthcare sector, has just celebrated its 10th Anniversary.
more...
A superior alternative for PLT users: Faecal Pancreatic Elastase Test
Pfizer recommends this test in a letter it sent to pharmacists notifying them about the withdrawal of PLT.
more...
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
more...
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.
more...
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK
Fecal tumor M2-PK is an appropriately sensitve tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer.
more...
ISO-Certificate
Our ISO-Cerficate as pdf-download.
more...